These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 10872179)

  • 1. [Pharmacological profiles of latanoprost (Xalatan), a novel anti-glaucoma drug].
    Nomura S; Hashimoto M
    Nihon Yakurigaku Zasshi; 2000 May; 115(5):280-6. PubMed ID: 10872179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Latanoprost : an update of its use in glaucoma and ocular hypertension.
    Perry CM; McGavin JK; Culy CR; Ibbotson T
    Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of 15-keto latanoprost on intraocular pressure and aqueous humor dynamics in monkey eyes.
    Wang RF; Gagliuso DJ; Mittag TW; Podos SM
    Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4143-7. PubMed ID: 17724199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative study of latanoprost (Xalatan) and isopropyl unoprostone (Rescula) in normal and glaucomatous monkey eyes.
    Serle JB; Podos SM; Kitazawa Y; Wang RF
    Jpn J Ophthalmol; 1998; 42(2):95-100. PubMed ID: 9587840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug.
    Takagi Y; Nakajima T; Shimazaki A; Kageyama M; Matsugi T; Matsumura Y; Gabelt BT; Kaufman PL; Hara H
    Exp Eye Res; 2004 Apr; 78(4):767-76. PubMed ID: 15037111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models.
    Krauss AH; Impagnatiello F; Toris CB; Gale DC; Prasanna G; Borghi V; Chiroli V; Chong WK; Carreiro ST; Ongini E
    Exp Eye Res; 2011 Sep; 93(3):250-5. PubMed ID: 21396362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human experience and efficacy of omidenepag isopropyl (Eybelis®; Omlonti®): Discovery to approval of the novel non-prostaglandin EP2-receptor-selective agonist ocular hypotensive drug.
    Sharif NA
    Curr Opin Pharmacol; 2024 Feb; 74():102426. PubMed ID: 38168596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of Latanoprost 0.005% on aqueous humor flow and outflow facility in glaucoma patients: a double-masked placebo-controlled clinical study.
    Dinslage S; Hueber A; Diestelhorst M; Krieglstein G
    Graefes Arch Clin Exp Ophthalmol; 2004 Aug; 242(8):654-60. PubMed ID: 15241610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and mechanisms of intraocular pressure reduction with latanoprost and timolol in participants with ocular hypertension: a comparison of 1 and 6 weeks of treatment.
    Johnson TV; Fan S; Zhan G; Camras CB; Toris CB
    J Glaucoma; 2010 Aug; 19(6):356-64. PubMed ID: 20179619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma.
    Borghi V; Bastia E; Guzzetta M; Chiroli V; Toris CB; Batugo MR; Carreiro ST; Chong WK; Gale DC; Kucera DJ; Jia L; Prasanna G; Ongini E; Krauss AH; Impagnatiello F
    J Ocul Pharmacol Ther; 2010 Apr; 26(2):125-32. PubMed ID: 20415621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes.
    Toris CB; Camras CB; Yablonski ME
    Ophthalmology; 1993 Sep; 100(9):1297-304. PubMed ID: 8371915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.
    Easthope SE; Perry CM
    Drugs Aging; 2002; 19(3):231-48. PubMed ID: 12027782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostaglandin derivates as ocular hypotensive agents.
    Alm A
    Prog Retin Eye Res; 1998 Jul; 17(3):291-312. PubMed ID: 9695796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dual acting compound with latanoprost amide and nitric oxide releasing properties, shows ocular hypotensive effects in rabbits and dogs.
    Impagnatiello F; Borghi V; Gale DC; Batugo M; Guzzetta M; Brambilla S; Carreiro ST; Chong WK; Prasanna G; Chiroli V; Ongini E; Krauss AH
    Exp Eye Res; 2011 Sep; 93(3):243-9. PubMed ID: 21356209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microvascular effects of selective prostaglandin analogues in the eye with special reference to latanoprost and glaucoma treatment.
    Stjernschantz J; Selén G; Astin M; Resul B
    Prog Retin Eye Res; 2000 Jul; 19(4):459-96. PubMed ID: 10785618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between individual differences in intraocular pressure reduction and outflow facility due to latanoprost in normal-tension glaucoma patients.
    Kondo N; Sawada A; Yamamoto T; Taniguchi T
    Jpn J Ophthalmol; 2006; 50(1):20-4. PubMed ID: 16453183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostaglandin analogs in the treatment of glaucoma.
    Hejkal TW; Camras CB
    Semin Ophthalmol; 1999 Sep; 14(3):114-23. PubMed ID: 10790575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Randomized parallel group study of 0.0015% tafluprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension (comparison with 0.005% latanoprost ophthalmic solution)].
    Ge J; Li X; Sun X; He X; Zhang H
    Zhonghua Yan Ke Za Zhi; 2015 Feb; 51(2):95-102. PubMed ID: 25907999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.
    Netland PA; Landry T; Sullivan EK; Andrew R; Silver L; Weiner A; Mallick S; Dickerson J; Bergamini MV; Robertson SM; Davis AA;
    Am J Ophthalmol; 2001 Oct; 132(4):472-84. PubMed ID: 11589866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.